The Tecan-Fudan University Demo Lab opens in Shanghai
News Jun 24, 2013
The laboratory was opened in October 2012, at a ceremony attended by dignitaries, fellow scientists and colleagues from the Shanghai area. Equipped with an array of Tecan instruments, the laboratory serves as a technology hub for researchers and students in the department, and offers a perfect opportunity for potential Tecan customers in the Shanghai area to see Tecan systems in action.
The Demo Lab is extensively equipped with state-of-the-art instruments for researchers in drug discovery, including the innovative Freedom EVO® GenePaint™ solution for automating in situ hybridization, fluorescence in situ hybridization and immunohistochemistry technologies, Infinite® 200 PRO and Infinite M1000 PRO multimode microplate readers, and the HP D300 Digital Dispense.
Professor Yizhun Zhu, Dean of the School of Pharmacy at Fudan University, already has several Tecan instruments in his department, where the primary research focus is cardiovascular disease. He said: “The foundation of the Tecan-Fudan University Demo Lab reflects the excellent cooperation that has built up between universities and enterprise. The Demo Lab serves as a window for potential customers of Tecan instruments, where they can look in detail at how different assays and screening applications can be performed using this equipment. This is a perfect win-win situation, where Tecan’s reliable and high quality products and services will undoubtedly accelerate the development of scientific research in drug discovery within our school. We look forward to a successful partnership and expect to see many exciting developments as we work together in the future.”
David Martyr, CEO of Tecan Group, added: “The foundation of the Tecan-Fudan University Demo Lab gives both Tecan and the School of Pharmacy an excellent opportunity to learn from each other. We hope that our work together will accelerate drug discovery and result in the publication of many groundbreaking scientific papers. China is now one of Tecan’s most important markets, and we look forward to an extensive and long-term collaborative partnership with Fudan University.”
A new study reveals that preventive medications – such as those to lower blood pressure or cholesterol, or to protect bone health, among others – are commonly prescribed during the last year of life of older adults with cancer, even though they are unlikely to provide meaningful benefits.READ MORE